User:Aivu93/sandbox: Difference between revisions
Content deleted Content added
m add citation and reference |
m change the reference |
||
| Line 1: | Line 1: | ||
Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to α4β1-integrin.<ref>{{Cite journal|last=Hutchinson|first=Michael|date=2007 |
Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to α4β1-integrin.<ref>{{Cite journal|last=Hutchinson|first=Michael|date=2007|title=Natalizumab: A new treatment for relapsing remitting multiple sclerosis|url=https://www.dovepress.com/natalizumab-a-new-treatment-for-relapsing-remitting-multiple-sclerosis-peer-reviewed-article-TCRM|journal=Therapeutics and Clinical Risk Management|language=en|volume=3|issue=2|pages=259–268|doi=10.2147/tcrm.2007.3.2.259|issn=1176-6336|via=}}</ref> |
||
<references /> |
<references /> |
||
Latest revision as of 19:00, 3 October 2019
Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to α4β1-integrin.[1]
- ^ Hutchinson, Michael (2007). "Natalizumab: A new treatment for relapsing remitting multiple sclerosis". Therapeutics and Clinical Risk Management. 3 (2): 259–268. doi:10.2147/tcrm.2007.3.2.259. ISSN 1176-6336.
{{cite journal}}: CS1 maint: unflagged free DOI (link)